Implementation requires detailed scheduling of sessions, follow-up meetings, and regular check-ins with healthcare professionals. AEF0117, developed by Aelis Farma, is the first of the new pharmacologic class, CB1-SSi, which is based on a unique mechanism of action that enables CB1-SSi to inhibit only the cellular signals involved in CUD. This breakthrough approach differs from previous CB1 receptor antagonists that, due to their broad blockade of all CB1 receptor activity, caused significant adverse effects preventing their clinical use.
- While there are no FDA-approved medications available for CUD, some studies show potential off-label utility in mitigating withdrawal and maintaining abstinence.
- In general, best practices in addiction treatment emphasize a chronic management model in the outpatient setting—rather than residential rehabilitation or inpatient hospitalization—for acute and maintenance treatment for substance use disorder.
All participants evidenced significant reductions in frequency of marijuana use and marijuana-related problems; however, no significant between-group differences emerged. In addition, where almost two thirds of all participants achieved initial posttreatment abstinence, only 14% maintained abstinence at one-year follow-up. Additionally, the utilization of computerized or mobile programs harnessing technology holds significant appeal for young adults, offering convenient platforms to bolster motivation and facilitate self-monitoring. By integrating young adults’ peer networks, these interventions provide essential accountability and support.
Additionally, the majority of existing studies have not included follow-up assessments beyond 12 months from treatment, and outcomes have tended to be most positive at the end of treatment or at short-term follow-up (e.g., refs. 112, 121). The effects of treatment over the long-term therefore require further investigation and it appears that sustained abstinence remains problematic. The addition of “booster” sessions after treatment may extend positive treatment effects. For example, following 9 sessions of MET and CBT, improved abstinence rates and fewer days of cannabis use were observed among adults with CUD who received maintenance checks at 1 and 4 months after treatment, compared with those in a “no-check” control condition (132). Rooke and colleagues conducted a two-arm, randomized clinical trial of an Internet-based, self-guided, self-help intervention called “Reduce Your Use” (RYU)82 RYU is a remotely administered, 6-module, self-guided intervention based on CBT and MI principles. Rooke et al. compared RYU to a 6-module educational control condition among 225 cannabis users.
Technologically Based Interventions
Research indicates that high-potency cannabis users experience more severe withdrawal symptoms compared to those using lower-potency products. The intensity of these symptoms often drives continued use, creating a cycle of dependency that becomes increasingly difficult to break. The American Psychiatric Association’s most recent criteria for substance use disorders include tools to identify cannabis addiction. For someone to be considered addicted, he or she must meet at least two of the 11 criteria, which include an inability to reduce consumption, constant cravings, and relationship and social problems. A Yale Medicine-led study identified several gene variants that increase risk of cannabis dependence.
Genetic and Environmental Risk Factors:
In Fischer et al. (2016), study participants were randomized to receive either brief oral or written cannabis interventions (C-O or C-W) focused on health risks and motivational strategies to reduce cannabis use, or parallel general health information control conditions (H-O and H-W). Those receiving the combined C-O plus C-W cannabis interventions significantly reduced their number of days of cannabis use over 3 months, lowering use from 23.79 days at baseline to 22.41 days at follow-up 25. Given age-specific variability in the patterns and contexts underlying disordered cannabis use and its consequences, interventions tailored to specific developmental stages may confer superior treatment outcomes. Adolescents and young adults frequently initiate cannabis use recreationally and socially, often lacking insights into problematic behaviors. Thus, psychoeducation and motivational enhancement strategies could potentiate other therapies, for instance.
What are cannabinoids?
- Additionally, evidence suggests potential gender differences in treatment response that may inform further personalization of interventions.
- This network complements the sample treatment plan for cannabis use disorder by providing additional layers of accountability and motivation.
- Hence, holistic interventions blending technology-based supports, distress prevention skill building, and positive peer influence optimization demonstrates high promise for reducing cannabis misuse among young adults.
- Many people search for effective methods to overcome substance challenges, and a sample treatment plan for cannabis use disorder offers a clear, step-by-step approach that may help individuals recover.
Dr Cooper disclosed that she is a consultant for, and has done research for, Canopy Growth Corporation. Healthcare providers may recommend cognitive and behavioral therapies alone or in combination with medications. Treatment for CUD marijuana addiction often requires continuing care to be effective, as CUD is a chronic condition with the potential for both recovery and relapse. According to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-5), you must have at least two signs in the symptoms section for over 12 months to be diagnosed with cannabis use disorder. Research shows that mental health conditions may contribute to SUD, and SUD can contribute to the development of mental health conditions. Seeking medical care as soon as you have signs of cannabis use disorder is essential.
Several medications have anticraving properties in addition to their primary mechanisms (19). Naltrexone, a mu-opioid receptor antagonist, has been approved by the FDA for alcohol and opioid use disorders as well as (in combination form with bupropion) binge eating disorder. A single daily dose of 50 mg of naltrexone can also generally help reduce cravings for other intoxicants and curb impulsive behaviors, such as those related to gambling. Addressing ambivalence is a universal aspect of management of substance use disorder. Once connected to specialty treatment, patients with cannabis use disorder often acknowledge spending an excessive amount of time or money on cannabis and a desire to reduce or stop use despite an ongoing attachment to the drug cannabis use disorder and a preference for how they feel while using compared with while not using. Starting with the initial assessment, the clinician can glean vocabulary, patient perspectives, and priorities that will subsequently allow for motivational work to reinforce patients’ “change talk” in a motivational interviewing framework (18).
Two reviewers extracted key data (e.g., study design, sample sizes, demographics, diagnostic criteria, interventions, and outcomes of interest). Any discrepancies in the extracted data were discussed until consensus was reached. The key efficacy outcome measures evaluated across included studies were abstinence, reduction in cannabis use frequency or quantity, withdrawal symptoms, cravings, and treatment retention. The severity of cannabis addiction varies among individuals, with diagnosis requiring at least two symptoms within a 12-month period. Research indicates that 9% of cannabis users develop dependence, rising to 17% for those who start during teenage years. “There is an urgent need to develop effective treatments, either behavioral or pharmacological, for cannabis use disorder,” says Yale Medicine psychiatrist Deepak Cyril D’Souza, MD, a Yale Medicine psychiatrist.
The power of Medical Marijuana Seeds
For which treatment by naltrexone or naloxone prevents the ability of opiates to affect the brain by binding the mu opioid receptor. Rimonabant is an antagonist at the CB1 receptor, and an early human laboratory study showed that rimonabant reduced the subjective effects and “high” of cannabis administration (see Huestis et al from 2001 and from 2009). However, clinical research investigating rimonabant as a potential treatment for obesity were stopped when it was discovered that it produced increased anxiety, depression and suicidality. As we described in ASAM https://mega-agro.com/genetics-of-substance-use-disorders-a-review/ Magazine previously, research is now being conducted to develop a medication that would partially blocks the CB1 receptor, in such a way that it would decrease the subjective effects of cannabis, but avoid these side effects.
As with most psychiatric conditions, patients would ideally not need to choose between pharmacotherapy or psychotherapy; a combination approach is ideal (Figure 1). Given the limitations on the efficacy of medications for treating patients with cannabis use disorder, intensive psychosocial approaches take on additional importance. Medications often help retain patients in care long enough for them to better respond to psychosocial and behavioral interventions for substance use disorders. Research and clinical reviews show that structured interventions combining behavioral therapy, counseling, and medical support can help reduce dependency.
The comparative effectiveness of current CUD interventions across adolescents, young adults, and older adults remains unknown. Our systematic review aimed to examine the literature with the hopes of bridging this gap in the existing literature by examining the efficacy of pharmacological and non-pharmacological interventions for cannabis use disorder across age groups. If successful, findings from our study will help to establish age-specific evidence-based strategies for the treatment of CUD, besides future directions in clinical research, to improve the assessment and management of this growing public health concern. Among regular users, cannabis use can lead to physiologic dependence, with withdrawal symptoms similar to that of other substance use disorders.